港股异动 | 康方生物-B(9926.HK)涨超8% 旗下PD-1获FDA突破性疗法认定
格隆汇3月30日丨 康方生物-B(9926.HK)涨超8%，报51.2港元，总市值418亿港元。
康方生物今日发布公告，公司与中国生物制药(01177.HK)共同开发的PD-1单抗药物派安普利单抗(安尼可)(研发代号：AK105)三线治疗转移性鼻咽癌，获得美国食品药品监督管理局(“FDA”)授予突破性疗法认定。
这是继FDA授予派安普利单抗三线治疗转移性鼻咽癌快速审批通道和孤儿药资格后，派安普利在美国取得的又一重要进展。这也是公司第二个肿瘤药物获得突破性疗法认定。
中国生物制药(01177.HK)则涨约2%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10